Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 2/20 | 0.49 |
| ▸ | PLAU | P00749 | 2/20 | 0.47 |
| ▸ | TSLP | Q969D9 | 4/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.44 |
| ▸ | MC4R | P32245 | 8/20 | 0.44 |
| ▸ | MC5R | P33032 | 8/20 | 0.44 |
| ▸ | MC3R | P41968 | 8/20 | 0.44 |
| ▸ | MC1R | Q01726 | 8/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGAV | P06756 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16450932 | 0.81 | CTSG (0.54) | CTSGPLAUTSLPKLKB1MC4R | |
| SCHEMBL13319649 | 0.77 | CTSG (0.69) | CTSGPLAUTSLPKLKB1 | |
| SCHEMBL10033237 | 0.73 | ITGB3 (0.64) | CTSGPLAUTSLPKLKB1MC4R | |
| SCHEMBL13351721 | 0.73 | CTSG (0.62) | CTSGPLAUTSLPKLKB1MC4R | |
| SCHEMBL13659870 | 0.72 | CTSG (0.59) | CTSGPLAUTSLPKLKB1MC4R | |
| SCHEMBL14096946 | 0.71 | MC4R (0.59) | CTSGPLAUTSLPKLKB1MC4R | |
| SCHEMBL14096826 | 0.71 | CTSG (0.59) | CTSGPLAUTSLPKLKB1MC4R | |
| SCHEMBL14096793 | 0.71 | CTSG (0.65) | CTSGPLAUKLKB1MC4RMC5R | |
| SCHEMBL14096800 | 0.71 | CTSG (0.65) | CTSGPLAUKLKB1MC4RMC5R | |
| SCHEMBL14096799 | 0.71 | CTSG (0.57) | CTSGPLAUTSLPKLKB1MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170022497-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | Arrowhead Pharmaceuticals, Inc. | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022497-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | PAM, PLAUR, M6PR | CTSG 855/4885PLAU 65/4885TSLP 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.